Open Access<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>
Author(s) -
Rimple Jeet Kaur,
Jaykaran Charan,
Siddhartha Dutta,
Paras Sharma,
Pankaj Bhardwaj,
Praveen Sharma,
Halyna Lugova,
Ambigga Krishnapillai,
Salequl Islam,
Mainul Haque,
Sanjeev Misra
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s287934
Subject(s) - favipiravir , medicine , pharmacovigilance , nausea , adverse effect , vomiting , drug , intensive care medicine , adverse drug reaction , covid-19 , pharmacology , disease , infectious disease (medical specialty)
COVID-19 caused by SARS-CoV-2 virus emerged as an unprecedented challenge to discover effective drugs for its prevention and cure. Hyperinflammation-induced lung damage is one of the poor prognostic indicators causing a higher rate of morbidity and mortality of COVID-19 patients. Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety. Thus, the present study was undertaken to evaluate the adverse drug events (ADEs) reported in the WHO pharmacovigilance database.